

Prolonged QRS duration in patients with heart failure: relation to exercise tolerance, diastolic function and aetiology

Ewa Straburzyńska-Migaj, Andrzej Szyszka, Andrzej Cieśliński

I Department and Chair of Cardiology, Medical University, Poznan, Poland

Abstract

Background: In patients with chronic heart failure (CHF) QRS prolongation is a frequent finding and is related to increased morbidity and mortality. It is not clear if prolonged QRS in CHF of ischaemic origin (CAD) represents the same severity of the syndrome as in non-ischaemic (non-CAD) cardiomyopathy.

Aim: To assess the relationship between QRS duration and BNP levels, diastolic function and peak VO_2 in patients with CAD CHF and non-CAD CHF.

Methods: In 70 patients with left ventricular ejection fraction (LVEF) <45% [35 with left bundle branch block (LBBB)] echocardiography, cardiopulmonary exercise test and standard ECG were performed as well as BNP level was measured.

Results: Peak VO_2 was significantly lower, BNP level higher in patients with LBBB than those without LBBB. In the non-CAD CHF peak VO_2 was significantly lower, whereas BNP levels and restrictive filling pattern prevalence higher in the group with LBBB than without LBBB, which was not seen in the CAD CHF group. A significant correlation between peak VO_2 and BNP levels ($r=-0.31$; $p=0.02$), QRS duration ($r=-0.27$; $p=0.02$), and diastolic function parameter - DTE ($r=0.28$; $p=0.02$) was found. Peak VO_2 was significantly lower in the CAD CHF than in non-CAD CHF. In multivariate regression analysis, LVEF ($r=-0.32$; $p=0.012$) and LVEDD ($r=0.30$; $p=0.015$) were independently associated with QRS duration.

Conclusion: In patients with CHF, QRS duration is independently related to LVEF and LVEDD. It seems that prolonged QRS may be a better predictor of more advanced CHF in patients with non-ischaemic rather than ischaemic cardiomyopathy.

Key words: heart failure, prolonged QRS, peak VO_2 , BNP, diastolic function

Kardiologia Polska 2008; 66: 1251-1257

In patients with chronic heart failure (CHF) QRS prolongation is a frequent finding and is related to increased morbidity and mortality [1-3]. It has been shown that left bundle branch block (LBBB) is associated with more severe left ventricular diastolic dysfunction and higher NT-proBNP levels in patients with CHF [4]. Left ventricular (LV) diastolic dysfunction is a common finding in patients with systolic CHF. Severe diastolic dysfunction, which is defined as LV restrictive filling pattern (RFP), is a predictor of reduced survival rate and exercise capacity in patients with CHF [5, 6]. Heart failure is also characterised by elevated natriuretic peptides levels. Plasma BNP levels provide prognostic information in patients with CHF [7]. It has been shown that elevated BNP levels are associated with the RFP [8, 9]. BNP has been reported to be an independent predictor of peak VO_2 [10]. It has also been shown that aetiology of CHF influences peak VO_2 [11, 12]. It is not clear whether prolonged QRS in CHF of ischaemic

origin (CAD-CHF) represents the same severity of the syndrome as in non-ischaemic CHF (non-CADCHF) [2, 13].

Our aim was to assess whether the presence of prolonged QRS is associated with BNP levels, diastolic function and exercise capacity in patients with clinically stable systolic CAD-CHF and non-CAD CHF.

Methods

Patients

The study group consisted of 88 consecutive patients with CHF and LV ejection fraction (LVEF) <45% referred to our department for diagnostic evaluation (coronary angiography, exercise capacity, consideration of heart transplantation) who were included in the studies evaluating the prevalence of angiotensin-converting enzyme polymorphisms in CHF [14] and the relationship between cytokines and pulmonary function and exercise intolerance in CHF [15]. Exclusion criteria were: severe renal failure, significant pulmonary disease,

Address for correspondence:

Ewa Straburzyńska-Migaj MD, PhD, I Klinika i Katedra Kardiologii, Uniwersytet Medyczny, Długa 1/2, 61-848 Poznań, tel.: +48 61 854 91 46, e-mail: ewa.migaj-straburzynska@sk1.am.poznan.pl

Received: 16 May 2008. Accepted: 01 October 2008.

acute infection, chronic inflammatory disease, cancer, coronary event or revascularisation in the previous 3 months. Only patients with sinus rhythm were included in the present study, and there were 70 such patients (mean age 51.9 ± 10.1 years, LVEF 26.8 ± 7.9 % and NYHA class 2.5 ± 0.8). Ischaemic heart disease was diagnosed in 35 (50%) patients (>50% stenosis of at least 1 major epicardial branch at angiography) and non-CAD CHF in 35 patients. All patients were in stable clinical condition. They were on optimal stable pharmacological therapy for at least 2 weeks before investigation (Table I).

The study protocol was approved by the local Ethics Committee of the University of Medical Sciences and informed consent was obtained from each patient.

Echocardiography

All patients underwent 2D and Doppler echocardiography (ECHO) with a Hewlett-Packard Sonos 5500 device and 2.5 MHz transducer. LVEF was calculated from the 4-chamber view using modified Simpson's algorithm. Doppler recordings from the mitral inflow were obtained from the apical 4-chamber view to assess LV filling pattern. We evaluated peak early (E wave) and late (A wave) transmitral velocities, E/A ratio, and deceleration time of E wave (DTE). Left ventricular RFP was defined as E/A ratio ≥ 2 or between 1 and 2 with DTE ≤ 130 ms.

Cardiopulmonary exercise treadmill test

All patients underwent maximal cardiopulmonary exercise treadmill test according to the Bruce protocol

modified by the addition of a stage 0 with 1.7 km/h and 5% gradient. The peak oxygen consumption (peak VO_2), carbon dioxide production (VCO_2), and minute ventilation (VE) were measured using the breath-by-breath technique (Sensor Medics, model V max29). The system was calibrated with a standard gas mixture of known concentration before each test. A standard 12-lead ECG was continuously recorded. All tests were terminated because of fatigue and/or dyspnoea. No test was terminated because of angina pectoris or arrhythmia. Peak VO_2 was calculated as an average value during the last 20 s of exercise.

Resting ECG

A 12-lead ECG was performed in every patient in resting supine position for measurement of QRS duration, which was computer read with the Marquette Mac System.

Biochemical analysis

Fasting venous blood was drawn in the morning after at least 30 minutes of rest (supine position). BNP level was measured using the RIA method (SHIONORIA-BNP, CIS Bio International) and was available in 31 patients in the QRS ≥ 120 ms group and 25 in the QRS < 120 ms group.

Statistical analysis

The values are given as a mean \pm SD. The Mann-Whitney and Chi-square analyses were used to evaluate significance of differences between the groups. Correlations between variables were assessed using

Table I. Clinical characteristics of the whole group and patients with QRS < 120 vs. ≥ 120 ms

	Total	QRS < 120 ms (n=35)	QRS ≥ 120 ms (n=35)	p QRS < 120 vs. ≥ 120 ms
Age [years, mean \pm SD]	51.9 \pm 10.1	48 \pm 10	55 \pm 9	0.008
NYHA [class, mean \pm SD]	2.5 \pm 0.8	2.2 \pm 0.9	2.7 \pm 0.7	0.01
CAD (%)	35 (50)	37	63	0.03
QRS [ms, mean \pm SD]	125.6 \pm 31.4	100.7 \pm 10	150.4 \pm 25	< 0.0000
LVEF [%]	26.9 \pm 7.9	31.2 \pm 6.7	22.5 \pm 6.6	< 0.0001
LVEDD [mm, mean \pm SD]	70.2 \pm 8.8	66.7 \pm 7.3	73.7 \pm 8.8	0.001
BNP [pg/ml, mean \pm SD]	69.0 \pm 65.8	44 \pm 38	89 \pm 76	0.008
Peak VO_2 [ml/kg/min, mean \pm SD]	16.5 \pm 4.7	18.1 \pm 4.4	15.0 \pm 4.5	0.003
RFP (%)	30 (42.9)	12 (34)	18 (51)	NS
ACEI (%)	66 (94)	33 (94)	33 (94)	NS
Beta blockers (%)	53 (76)	27 (77)	26 (74)	NS
Digoxin (%)	34 (49)	20 (57)	14 (40)	NS
Furosemide (%)	56 (76)	25 (71)	31 (89)	0.07
Statins (%)	32 (46)	13 (37)	19 (54)	NS
Acetylsalicylic acid (%)	40 (57)	19 (54)	21 (60)	NS
Antiarrhythmic drugs (%)	24 (34)	8 (23)	16 (46)	0.04

Abbreviations: CAD – coronary artery disease, LVEF – left ventricular ejection fraction, LVEDD – left ventricular end-diastolic diameter, BNP – B-type natriuretic peptide, RFP – restrictive filling pattern, ACEI – angiotensin converting enzyme inhibitors

Spearman rank test. Multivariate regression analysis was used to assess which of the statistically significant correlations between variables were independently correlated with QRS width. A p value of <0.05 was considered as statistically significant. All analyses were performed using the Statistica 7.0 package.

Results

Patient's characteristics and comparison between groups with and without QRS prolongation are summarised in Table I. There were 35 patients with QRS <120 ms (group I) and 35 with QRS \geq 120 ms (group II). In all patients with prolonged QRS, the LBBB morphology was present. There was a significant difference in age between the two groups with slightly older patients in group II. Group I patients had significantly higher LVEF and peak VO₂, and significantly lower NYHA class and BNP levels compared to group II. There was no significant difference in the percentage of patients with RFP. There was no significant difference in the treatment between the two groups with only a trend for higher prevalence of furosemide and antiarrhythmic treatment in the LBBB group.

In patients with CAD CHF 13 had normal QRS and 22 had LBBB (Table II). In patients with non-CAD CHF, 22 had

normal QRS and 13 had LBBB (Figure 1). In patients with CAD CHF there were no significant differences between groups with or without LBBB in peak VO₂, BNP levels and severe diastolic dysfunction prevalence (Table II). In contrast, in patients with non-CAD CHF (Table III) there were significant differences between groups with or without LBBB in peak VO₂, BNP levels and severe diastolic dysfunction prevalence.

In the whole group there was a significant inverse correlation between QRS duration and peak VO₂ and LVEF, a significant positive correlation between QRS and LV end-diastolic diameter (LVEDD) (Figure 2), a weak but significant correlation between QRS and age ($r=0.24$; $p=0.04$), and a non-significant trend for QRS and BNP levels ($r=0.26$; $p=0.052$). In non-CAD CHF correlations between QRS and LVEF, BNP, peak VO₂, and LVEDD were significant, but there was no correlation between QRS and age (data not presented). In the CAD CHF group only correlations between QRS and age and LVEDD remained significant.

There was a significant correlation between peak VO₂ and the parameter of diastolic function DTE ($r=0.28$; $p=0.02$). Furthermore, peak VO₂ was significantly lower in CAD CHF in comparison to non-CAD CHF (14.7 ± 4.8 vs. 18.4 ± 3.8 ml/kg/min; $p=0.0009$). In the multivariate regression analysis (including age, LVEF, LVEDD, presence

Table II. Characteristics of patients with CAD in relation to QRS width

	Total (n=35)	QRS <120 ms (n=13)	QRS \geq 120 ms (n=22)	p QRS<120 vs. \geq 120 ms
QRS [ms, mean \pm SD]		100.6 \pm 7.6	143 \pm 23.9	<0.0001
Age [years, mean \pm SD]	54.9 \pm 7.5	52.8 \pm 9.1	65.2 \pm 6.2	NS
LVEF [%, mean \pm SD]	26.1 \pm 7.2	30.6 \pm 5.3	23.4 \pm 6.8	0.003
LVEDD [mm, mean \pm SD]	70.5 \pm 8.9	65.3 \pm 6.5	73.6 \pm 8.8	0.008
Peak VO ₂ [ml/kg/min, mean \pm SD]	14.7 \pm 4.8	15.4 \pm 4.8	14.3 \pm 4.9	NS
BNP [pg/ml, mean \pm SD]	80.5 \pm 67.8	61.9 \pm 48	90.3 \pm 75.5	NS
RFP (%)	16 (60)	6 (46)	10 (45)	NS

Abbreviations: as in Table I

Table III. Characteristics of patients with non-CAD CHF in relation to QRS width

	Total (n=35)	QRS <120 ms (n=22)	QRS \geq 120 ms (n=13)	p QRS<120 vs. \geq 120 ms
QRS [ms, mean \pm SD]		100.7 \pm 10.7	162 \pm 23	<0.0001
Age [years, mean \pm SD]	49.0 \pm 11.6	45.8 \pm 10.1	54.4 \pm 12.3	NS
LVEF [%, mean \pm SD]	27.6 \pm 8.6	31.5 \pm 7.4	20.8 \pm 6.0	0.0003
LVEDD [mm, mean \pm SD]	69.9 \pm 8.7	67.5 \pm 7.7	74.0 \pm 9.1	0.056
Peak VO ₂ [ml/kg/min, mean \pm SD]	18.4 \pm 3.8	19.6 \pm 3.4	16.3 \pm 3.6	0.009
BNP [pg/ml, mean \pm SD]	56.8 \pm 62.4	32.4 \pm 27.2	87.3 \pm 80.3	0.02
RFP (%)	14 (40)	6 (27)	8 (62)	0.045

Abbreviations: as in Table I




Figure 1. Individual values of QRS width in patients with ischaemic (CAD) and nonischaemic (non-CAD) CHF

of RFP, aetiology and peak VO_2) LVEF ($\beta = -0.32$; $p = 0.012$) and LVEDD ($\beta = 0.30$; $p = 0.015$) were independently associated with QRS duration. The same analysis for the non-CAD CHF patients showed an independent association with LVEF, whereas for the CAD CHF group there was not such a correlation.

Discussion

We showed that in patients with CHF, QRS width was independently related to LVEF and LVEDD. Interestingly, we also showed that prolonged QRS may be a better predictor of more advanced CHF in patients with non-CAD rather than CAD-CHF.

Our patients with prolonged QRS duration had lower peak VO_2 together with LVEF and LVEDD (which are similar findings to those of Kalra et al. [3]) and BNP levels were higher in comparison to patients with normal QRS duration. All these parameters are important prognostic indicators in CHF [7, 16]. Many studies have shown that biventricular pacing improves LVEF, LVEDD, peak VO_2 and prognosis in patients with CHF and prolonged QRS [17, 18]. Peak VO_2 is an established measure of exercise capacity in patients with CHF and it is an important prognostic marker when considering transplantation and prognosis [19]. In severe CHF, patients with ischaemic heart disease have worse prognosis than those with dilated non-ischaemic cardiomyopathy [20]. It has been suggested that aetiology of heart failure may influence functional capacity [11, 12, 21]. Our results are in agreement with these observations. Patients with ischaemic aetiology had significantly lower peak VO_2 than patients with non-ischaemic CHF. As in the study of De Feo et al. [11], patients with CAD were older. Ischaemic aetiology was also an independent predictor of exercise tolerance in patients with




Figure 2. Correlations between QRS duration and pVO_2 , LVEDD and LVEF

CHF in the study of Duncan et al. [22], besides total isovolumetric time, which is determined by LBBB. In CAD CHF exercise may be associated with worse adaptation to excessive wall stress than in non-ischaemic cardiomyopathy due to the presence of akinetic or dyskinetic cardiac

segments and variable degree of mitral regurgitation [23]. Moreover, CAD might be associated with more widespread peripheral vascular disease.

A common finding in patients with systolic CHF is LV diastolic dysfunction. It has been shown in different studies that among other things, severe diastolic dysfunction, which is defined as RFP, is a predictor of lower survival rate and reduced exercise capacity in patients with CHF [24]. Surprisingly, we found that prevalence of severe diastolic dysfunction in patients with CAD was independent of QRS duration, but in patients with non-CAD CHF it was significantly more frequently found in the group with prolonged QRS than in patients with normal QRS.

Up to 50% of patients with CHF have a prolonged QRS complex, mostly presenting as LBBB, which has been identified as an indicator of adverse prognosis, and intraventricular conduction delays, which result in abnormal depolarisation of the heart and mechanical asynchrony of ventricles. These QRS abnormalities have been suggested to be responsible for increased morbidity and mortality [25-27]. Prolonged QRS duration is also associated with worse NYHA class, peak VO_2 and LVEF, which is in line with our observations [3]. Bruch et al [4] found that in patients with CHF and comparable systolic LV function, LBBB was associated with more severe diastolic dysfunction and higher NT-proBNP levels. The prevalence of RFP in their group was significantly higher in patients with rather than without LBBB. They concluded that these findings may contribute to increased morbidity and mortality in patients with CHF and LBBB. It was shown in another study that in patients with systolic CHF, the RFP indeed adds incremental value to QRS duration in determining prognosis [28]. These investigators did not analyse prevalence of RFP in relation to the aetiology of CHF and QRS duration.

In our study the prevalence of RFP was similar in patients with CAD and LBBB and those without LBBB, but was significantly higher in patients with rather than without LBBB and non-CAD CHF. Furthermore, LBBB in non-CAD CHF was associated with significantly lower peak VO_2 and higher BNP levels in comparison to the no-LBBB group, which was not observed in the CAD group. These findings may suggest that prolonged QRS may be a better predictor of more severe CHF in patients with non-ischaemic CHF than with ischaemic heart disease. This may be an explanation why patients with prolonged QRS with non-ischaemic cardiomyopathy may have worse prognosis [13]. Interestingly, improvements in patients treated with resynchronisation therapy were greater in patients with non-ischaemic than rather ischaemic cause of CHF [29]. To confirm these suggestions further studies with a higher number of patients are needed.

Conclusions

In patients with CHF, QRS duration is independently related to LVEF and LVEDD. It seems that prolonged QRS

may be a better predictor of more advanced CHF in patients with non-ischaemic than with ischaemic cardiomyopathy.

References

1. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. *J Am Coll Cardiol* 2005; 46: 2183-92.
2. Luliano S, Fisher SG, Karasik PE, et al. QRS duration and mortality in patients with congestive heart failure. *Am Heart J* 2002; 143: 1085-91.
3. Kalra PR, Sharma R, Shamim W, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. *Int J Cardiol* 2002; 86: 225-31.
4. Bruch C, Stypmann J, Grude M, et al. Left bundle branch block in chronic heart failure – impact on diastolic function, filling pressures, and B-type natriuretic peptide. *J Am Soc Echocardiogr* 2006; 19: 95-100.
5. Whalley GA, Gamble GD, Doughty RN. The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis. *Int J Cardiol* 2007; 116: 70-7.
6. Patrianakos AP, Parthenakis FI, Papadimitriou EA, et al. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. *Eur J Heart Fail* 2004; 6: 735-43.
7. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. *Circulation* 1997; 96: 509-16.
8. Yu MC, Sanderson JE, Shum IO, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. *Eur Heart J* 1996; 17: 1694-702.
9. Straburzyńska-Migaj E, Szyszka A, Trojnarowska O, et al. Restrictive filling pattern predicts pulmonary hypertension and is associated with increased BNP levels and impaired exercise capacity in patients with heart failure. *Kardiologia Pol* 2007; 65: 1049-55.
10. Krüger S, Graf J, Kunz D, et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. *J Am Coll Cardiol* 2002; 40: 718-22.
11. De Feo S, Franceschini L, Brighetti G, et al. Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity. *Int J Cardiol* 2005; 104: 292-7.
12. Juillière Y, Grentzinger A, Houplon P, et al. Role of etiology of cardiomyopathies on exercise capacity and oxygen consumption in patients with severe congestive heart failure. *Int J Cardiol* 2000; 73: 251-5.
13. Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. *Am J Cardiol* 1995; 75: 460-4.
14. Straburzyńska-Migaj E, Ochotny R, Chmara E, et al. Angiotensin converting enzyme gene polymorphism in patients with heart failure. *Folia Cardiol* 2005; 12: 103-10.
15. Straburzyńska-Migaj E, Ochotny R, Straburzyńska-Lupa A, et al. Cytokiny a czynność układu oddechowego i nietolerancja wysiłku w niewydolności serca. *Pol Przegl Kard* 2005; 7: 129-35.
16. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart

- failure. The V-HeFT VA Cooperative Studies Group. *Circulation* 1993; 87: V15-16.
17. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140-50.
 18. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. *N Engl J Med* 2005; 352: 1539-49.
 19. Mancini D, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation* 1991; 83: 778-86.
 20. Arena R, Tevald M, Peberdy MA. Influence of etiology on ventilatory expired gas and prognosis in heart failure. *Int J Cardiol* 2005; 99: 217-23.
 21. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. *Am J Cardiol* 1987; 59: 634-8.
 22. Duncan AM, Francis DP, Gibson DG, et al. Limitation of exercise tolerance in chronic heart failure: distinct effects of left bundle-branch block and coronary artery disease. *J Am Coll Cardiol* 2004; 43: 1524-31.
 23. Hayashida W, Kumada T, Nohara R, et al. Left ventricular regional wall stress in dilated cardiomyopathy. *Circulation* 1990; 82: 2075-83.
 24. Lapu-Bula R, Robert A, De Kock M, et al. Relation of exercise capacity to left ventricular systolic function and diastolic filling in idiopathic or ischemic cardiomyopathy. *Am J Cardiol* 1999; 83: 728-34.
 25. Shamim W, Francis DP, Yousufuddin M, et al. Intraventricular conduction delay: a predictor of mortality in chronic heart failure? *Int J Cardiol* 1999; 70: 171-8.
 26. Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block: the effect of interventricular asynchrony. *Circulation* 1989; 79: 845-53.
 27. Erlenbacher JA, Barbarash S. Intraventricular conduction delay and functional mitral regurgitation. *Am J Cardiol* 2001; 88: 83-6.
 28. Bruch C, Gotzmann M, Stypmann J, et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure. *J Am Coll Cardiol* 2005; 45: 1072-5.
 29. Sutton MGSJ, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. *Circulation* 2003; 107: 1985-90.

Wydłużenie zespołu QRS u chorych z niewydolnością serca – związek z tolerancją wysiłku, czynnością rozkurczową i etiologią zespołu

Ewa Straburzyńska-Migaj, Andrzej Szyszka, Andrzej Cieśliński

I Klinika i Katedra Kardiologii, Uniwersytet Medyczny w Poznaniu

Streszczenie

Wstęp: U chorych z niewydolnością serca często spotyka się wydłużenie QRS, najczęściej o morfologii bloku lewej odnogi pęczka Hisa (LBBB). Jest ono uznanym czynnikiem ryzyka nagłego zgonu. Ponadto LBBB związane jest z bardziej zaawansowaną niewydolnością serca i wyższymi stężeniami NT-proBNP. Trwa dyskusja, czy wydłużenie QRS reprezentuje ten sam stopień zaawansowania choroby w niewydolności serca o podłożu choroby niedokrwiennej (CAD) i nieniedokrwiennej (non-CAD).

Cel: Zbadanie zależności pomiędzy obecnością wydłużonego QRS a stężeniem peptydu natriuretycznego typu B (BNP), czynnością rozkurczową lewej komory i tolerancją wysiłku u chorych ze stabilną klinicznie skurczową niewydolnością serca w zależności od etiologii niedokrwiennej i nieniedokrwiennej.

Metody: Grupę badaną stanowiło 70 chorych z niewydolnością serca (wiek $51,9 \pm 10,1$ roku) i obniżoną frakcją wyrzucania lewej komory (LVEF $< 45\%$, $26,8 \pm 7,9\%$), z rytmem zatokowym. U wszystkich wykonano standardowe badanie echokardiograficzne i maksymalny test spiroergometryczny na bieżni ruchomej. Restrykcyjny profil napływu mitralnego (RFP) rozpoznawano, gdy E/A > 2 lub pomiędzy 1 i 2 z czasem deceleracji fali E (DTE) < 130 ms. Tolerancję wysiłku oceniano jako $peak\ VO_2$. Czas trwania QRS mierzono automatycznie za pomocą systemu Marquette Mac System. Stężenia BNP mierzono metodą radioimmunologiczną.

Wyniki: W badanej grupie u 35 chorych (50%) stwierdzono wydłużenie QRS ≥ 120 ms o morfologii LBBB. Chorzy w grupie z QRS < 120 ms byli istotnie młodsi niż chorzy w grupie z QRS ≥ 120 ms, charakteryzowali się istotnie większą LVEF, $peak\ VO_2$ oraz istotnie niższą klasą wg NYHA i stężeniami BNP. Nie stwierdzono istotnych różnic między grupami w częstości występowania RFP oraz w odniesieniu do stosowanego leczenia. Spośród chorych z CAD u 13 stwierdzono QRS < 120 ms ($100,6 \pm 7,6$ ms), u 22 – QRS ≥ 120 ms ($143 \pm 23,9$ ms). Spośród chorych z kardiomiopatią nieniedokrwinną 22 miało QRS < 120 ms ($100,7 \pm 10,7$ ms), a 13 – QRS ≥ 120 ms (162 ± 23 ms, $p=0,015$ w porównaniu z grupą CAD). W grupie chorych z CAD nie stwierdzono istotnych różnic między podgrupami z LBBB i bez LBBB w odniesieniu do $peak\ VO_2$, stężeń BNP i częstości występowania RFP. Przeciwnie w grupie osób z kardiomiopatią nieniedokrwinną – chorzy z LBBB mieli istotnie mniejsze $peak\ VO_2$, większe stężenia BNP i częściej RFP niż chorzy bez LBBB. W całej badanej grupie istotne były korelacje pomiędzy czasem trwania QRS a $peak\ VO_2$, LVEF, wymiarem końcoworozkurczowym lewej komory serca (LVEDD) i wiekiem oraz tendencja ze stężeniami BNP. W analizie regresji z uwzględnieniem LVEF, LVEDD, wieku, obecności RFP, etiologii CHF i $peak\ VO_2$ wykazano, że niezależnie związane z czasem trwania QRS są LVEF i LVEDD.

Wnioski: U chorych z niewydolnością serca niezależnymi wskaźnikami szerokości QRS są LVEF i LVEDD. Wydłużenie QRS w standardowym EKG może wskazywać na bardziej zaawansowaną niewydolność serca u chorych z kardiomiopatią nieniedokrwinną. Nie stwierdzono takiej zależności w grupie z CAD.

Słowa kluczowe: niewydolność serca, wydłużony QRS, $peak\ VO_2$, BNP, czynność rozkurczowa

Kardiologia Pol 2008; 66: 1251-1257

Adres do korespondencji:

dr hab. n. med. Ewa Straburzyńska-Migaj, I Klinika i Katedra Kardiologii, Uniwersytet Medyczny, Długa 1/2, 61-848 Poznań, tel.: +48 61 854 91 46, e-mail: ewa.migaj-straburzynska@sk1.am.poznan.pl

Praca wpłynęła: 16.05.2008. Zaakceptowana do druku: 01.10.2008.